Business Description
Aptevo Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US03835L5049
Total Employee Number:
33Description
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.28 | |||||
Equity-to-Asset | 0.58 | |||||
Debt-to-Equity | 0.38 | |||||
Debt-to-EBITDA | -0.17 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 50.58 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.77 | |||||
9-Day RSI | 41.07 | |||||
14-Day RSI | 43.41 | |||||
3-1 Month Momentum % | 8.43 | |||||
6-1 Month Momentum % | -55.25 | |||||
12-1 Month Momentum % | -91.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.36 | |||||
Quick Ratio | 3.36 | |||||
Cash Ratio | 3.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -673.82 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -255.23 | |||||
ROA % | -133.88 | |||||
ROIC % | -438.61 | |||||
3-Year ROIIC % | -33.3 | |||||
ROC (Joel Greenblatt) % | -615.74 | |||||
ROCE % | -186.89 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.47 | |||||
Price-to-Tangible-Book | 0.47 | |||||
EV-to-EBIT | 0.17 | |||||
EV-to-EBITDA | 0.17 | |||||
EV-to-Forward-Revenue | 0.07 | |||||
EV-to-FCF | 0.16 | |||||
| Price-to-Net-Current-Asset-Value | 0.71 | |||||
| Price-to-Net-Cash | 0.88 | |||||
Earnings Yield (Greenblatt) % | 588.24 | |||||
FCF Yield % | -475.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:APVO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aptevo Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -203.661 | ||
| Beta | 2.786 | ||
| 3-Year Sharpe Ratio | -2.59 | ||
| 3-Year Sortino Ratio | -2.18 | ||
| Volatility % | 80.09 | ||
| 14-Day RSI | 43.41 | ||
| 14-Day ATR ($) | 0.270393 | ||
| 20-Day SMA ($) | 4.79875 | ||
| 12-1 Month Momentum % | -91.59 | ||
| 52-Week Range ($) | 3.8 - 59.399999 | ||
| Shares Outstanding (Mil) | 1.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aptevo Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aptevo Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 130 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 43 days | ||
| General meeting for 2026 | 2026-07-24 10:00 | In 26 days | ||
| First quarter earnings results for 2026 | 2026-05-13 | 4.83 (-0.31%) | ||
| Annual report for 2025 | 2026-03-26 | 4.43 (+4.30%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 4.43 (+4.30%) | ||
| The 38th Annual Roth Conference | 2026-03-23 13:30 | 4.56 (+5.80%) | ||
| 0.0555556:1 Stock Split | 2025-12-30 | 9.90 (+1.36%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 25.74 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-11 | 40.68 (+5.12%) |
Show
Entries
Aptevo Therapeutics Inc Frequently Asked Questions
What is Aptevo Therapeutics Inc(APVO)'s stock price today?
The current price of APVO is $4.55. The 52 week high of APVO is $59.40 and 52 week low is $3.80.
When is next earnings date of Aptevo Therapeutics Inc(APVO)?
The next earnings date of Aptevo Therapeutics Inc(APVO) is 2026-08-11 Est..
Does Aptevo Therapeutics Inc(APVO) pay dividends? If so, how much?
Aptevo Therapeutics Inc(APVO) does not pay dividend.
Guru Commentaries on NAS:APVO
No articles.
Press Release
Articles on Aptevo Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers